Methods of administering anti-ox40 antibodies

Abstract

The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.

1 - 130 . (canceled) 
     
     
         131 . A method for detecting OX40 in a sample comprising contacting said sample with an antibody that specifically binds to human OX40, the antibody comprising a VH comprising CDRs VH CDR1, VH CDR2, and VH CDR3; and a VL comprising CDRs VL CDR1, VL CDR2, and VL CDR3, wherein:
 (a) the VH comprises the VH CDR1, VH CDR2, and VH CDR3 amino acid sequences of the VH amino acid sequence set forth in SEQ ID NO: 16; and/or   (b) the VL comprises the VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the VL amino acid sequence set forth in SEQ ID NO: 15.   
     
     
         132 . The method of  claim 131 , wherein the antibody comprises the VH CDR1, VH CDR2, and VH CDR3 amino acid sequences set forth in SEQ ID NOs, 4, 5, and 6, respectively. 
     
     
         133 . The method of  claim 131 , wherein the antibody comprises the VL CDR1, VL CDR2, and VL CDR3 amino acid sequences set forth in SEQ ID NOs: 1, 2, and 3, respectively. 
     
     
         134 . The method of  claim 131 , wherein the antibody comprises the VH CDR1, VH CDR2, and VH CDR3 amino acid sequences set forth in SEQ ID NOs, 4, 5, and 6, respectively; and the VL CDR1, VL CDR2, and VL CDR3 amino acid sequences set forth in SEQ ID NOs: 1, 2, and 3, respectively. 
     
     
         135 . The method of  claim 131 , wherein the antibody comprises a VH comprising the amino acid sequence set forth in SEQ ID NO: 16. 
     
     
         136 . The method of  claim 131 , wherein the antibody comprises a VL comprising the amino acid sequence set forth in SEQ ID NO: 15. 
     
     
         137 . The method of  claim 131 , wherein antibody comprises a VH comprising the amino acid sequence set forth in SEQ ID NO: 16; and a VL comprising the amino acid sequence set forth in SEQ ID NO: 15. 
     
     
         138 . The method of  claim 131 , wherein the antibody comprises a heavy chain, wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 21, 23, 51, 52, 60, 61, 62, and 63. 
     
     
         139 . The method of  claim 131 , wherein the antibody comprises a light chain, wherein the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         140 . The method of  claim 131 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 21; and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         141 . The method of  claim 131 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 60; and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         142 . The method of  claim 131 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 23; and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         143 . The method of  claim 131 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 51; and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         144 . The method of  claim 131 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 52; and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         145 . The method of  claim 131 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 61; and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         146 . The method of  claim 131 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 62; and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         147 . The method of  claim 131 , wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 63; and the light chain comprises the amino acid sequence set forth in SEQ ID NO: 20. 
     
     
         148 . The method of  claim 131 , wherein the antibody further comprises a detectable label. 
     
     
         149 . The antibody of  claim 131 , further comprising:
 (a) a heavy chain constant region selected from the group consisting of human IgG 1 , IgG 2 , IgG 3 , IgG 4 , IgA 1 , and IgA 2 ; and/or   (b) a light chain constant region selected from the group consisting of human IgGκ and IgGλ.   
     
     
         150 . The antibody of  claim 149 , wherein:
 (a) the amino acid sequence of the IgG 1  heavy chain constant region comprises an N297A mutation, an N297Q mutation, or a mutation selected from the group consisting of D265A, P329A, and a combination thereof;   (b) the amino acid sequence of the IgG 4  heavy chain constant region comprises an S228P mutation; or   (c) the amino acid sequence of the IgG 2  heavy chain constant region comprises a C127S mutation,   numbered according to the EU index as in Kabat.